U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H18O8P2.4Na
Molecular Weight 516.2373
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FOSFESTROL SODIUM

SMILES

[Na+].[Na+].[Na+].[Na+].CC\C(C1=CC=C(OP([O-])([O-])=O)C=C1)=C(\CC)C2=CC=C(OP([O-])([O-])=O)C=C2

InChI

InChIKey=XGZAXRQNRRXUMY-MJCKVQKWSA-J
InChI=1S/C18H22O8P2.4Na/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24;;;;/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24);;;;/q;4*+1/p-4/b18-17+;;;;

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/083003.pdf | https://en.wikipedia.org/wiki/Diethylstilbestrol | http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-16.pdf

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

Originator

Dodds E.C. et al.
5
Sources: DOI: 10.1016/0305-7372(84)90049-5https://www.nature.com/articles/141247b0
Curator's Comment: Fosfestrol was developed in the research laboratories of Asta-Werke and introduced in 1952 for the therapy of metastasizing prostatic carcinoma under the name of Honvan.

Approval Year

1941
158
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 0.18 nM [EC50]
Agonist
2678
 0.06 nM [EC50]
Inverse Agonist
80
 10.0 µM [EC50]
Inverse Agonist
80
 700.0 nM [EC50]
Inverse Agonist
80
 700.0 nM [EC50]
estrogen receptor 1
5
Target ID: P03372
Gene Symbol: ESR1
Agonist
2678
Inverse Agonist
80
 1.0 µM [IC50]
Inverse Agonist
80
 1.0 µM [IC50]
Inverse Agonist
80
 1.0 µM [IC50]
estrogen receptor 2 (ER beta)
5
Target ID: Q92731
Gene Symbol: ESR2
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Stilphostrol

Approved Use

Unknown

Launch Date

1981
Primary
Approved
8429
STILBESTROL

Approved Use

Used in the treatment of prostate cancer.

Launch Date

1973
Preventing
Approved
8429
STILBESTROL

Approved Use

Prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.

Launch Date

1973
Primary
Approved
8429
STILBESTROL

Approved Use

It is used for the treatment of senile (atrophic) vaginitis.

Launch Date

1973
Primary
Approved
8429
STILBESTROL

Approved Use

It is used for the treatment of vulvar dystrophy.

Launch Date

1973
Primary
Approved
8429
STILBESTROL

Approved Use

Other therapeutic use of diethylstilbestrol was post menopause syndrome.

Launch Date

1973
Primary
Approved
8429
STILBESTROL

Approved Use

Drug is indicated for replacement therapy of estrogen deficiency associated with amenorrhea.

Launch Date

1973
Primary
Approved
8429
STILBESTROL

Approved Use

Drug is indicated for replacement therapy of estrogen deficiency associated with female hypogonadism.

Launch Date

1973
Preventing
Approved
8429
STILBESTROL

Approved Use

Drug is indicated for the prevention of osteoporosis.

Launch Date

1973
Doses

Doses

DosePopulationAdverse events​
1104 mg 1 times / day multiple, intravenous
Recommended
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12496896/
unhealthy, 56-87
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 56-87
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/12496896/
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12496896/
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10526944/
unhealthy, 59
n = 1
Health Status: unhealthy
Condition: prostate cancer
Age Group: 59
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10526944/
Disc. AE: Secondary adrenocortical insufficiency...
AEs leading to
discontinuation/dose reduction:
Secondary adrenocortical insufficiency
Sources:
https://pubmed.ncbi.nlm.nih.gov/10526944/
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
Disc. AE: Toxic reaction (NOS), Toxic reaction (NOS)...
AEs leading to
discontinuation/dose reduction:
Toxic reaction (NOS) (grade 2, 3 patients)
Toxic reaction (NOS) (grade 3, 2 patients)
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
DLT: Nausea and vomiting, Nausea and vomiting...
Dose limiting toxicities:
Nausea and vomiting (grade 1, 13 patients)
Nausea and vomiting (grade 2, 4 patients)
Weight gain (2 patients)
Edema (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Other AEs: Hypertension, Gynecomastia...
Other AEs:
Hypertension (5%)
Gynecomastia (38%)
Peripheral edema (32%)
Gastrointestinal discomfort (19%)
Deep vein thrombosis (8%)
Skin rash (5%)
Transaminases increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
Other AEs: Nausea, Bone pain...
Other AEs:
Nausea (17 patients)
Bone pain (17 patients)
Perineal pain (1 patient)
Deep vein thrombosis (4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
4 g 1 times / day multiple, intravenous
RP2D
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy
Health Status: unhealthy
Condition: prostate cancer
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
AEs

AEs

AESignificanceDosePopulation
Vomiting 1 patient
Disc. AE
1104 mg 1 times / day multiple, intravenous
Recommended
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12496896/
unhealthy, 56-87
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 56-87
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/12496896/
Secondary adrenocortical insufficiency Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10526944/
unhealthy, 59
n = 1
Health Status: unhealthy
Condition: prostate cancer
Age Group: 59
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10526944/
Toxic reaction (NOS) grade 2, 3 patients
Disc. AE
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
Toxic reaction (NOS) grade 3, 2 patients
Disc. AE
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi
Edema 2 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
Weight gain 2 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
Nausea and vomiting grade 1, 13 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
Nausea and vomiting grade 2, 4 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/7508621/
Gastrointestinal discomfort 19%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Transaminases increased 2%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Peripheral edema 32%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Gynecomastia 38%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Hypertension 5%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Skin rash 5%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Deep vein thrombosis 8%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/10761752/
Perineal pain 1 patient
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
Bone pain 17 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
Nausea 17 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
Deep vein thrombosis 4 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/9607886/
Sourcing

Sourcing

Vendor/AggregatorIDURL
A2Z Chemical
AZM13788
ABI Chem
AC1MHWYU
Aurora Fine Chemicals LLC
K16.450.167
http://online.aurorafinechemicals.com/info?ID=K16.450.167
BLD Pharm
BD131559
http://www.bldpharm.com/products/4719-75-9.html
BOC Sciences
4719-75-9
https://www.bocsci.com/tetrasodium-fosfestrol-cas-4719-75-9-item-15065.html
Changzhou Highassay Chemical Co., Ltd
my_sub1996
ChemMol
99096292
http://www.chemmol.com/chemmol/99096292.html
Glentham Life Sciences
GP2439
http://www.glentham.com/products/product/GP2439/
Hairui
HR110840
http://www.hairuichem.com/en/product/23519-26-8.html
NovoSeek
3034148
PubChem
3034148
https://pubchem.ncbi.nlm.nih.gov/compound/3034148
iChemical
EBD43877
http://www.ichemical.com/chemicals/cas-4719-75-9
PubMed

PubMed

TitleDatePubMed
Late effects in the vaginal and cervical epithelia after injections of diethylstilbestrol into neonatal mice.
1975 Jan 1
Follow-up study of male and female offspring of DES-treated mothers a preliminary report.
1975 Jul
Endometrial carcinoma after cyclical oestrogen-progestogen therapy for Turner's syndrome.
1975 May
The choice of estrogen preparations in the treatment of prostatic cancer.
1975 Nov 8
Induction of urogenital anomalies and some tumors in the progeny of mice receiving diethylstilbestrol during pregnancy.
1977 Apr
Effects of estrogenic agents on chitobiase activity in the epidermis and hepatopancreas of the fiddler crab, Uca pugilator.
1999 Feb
Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na+, K+ -ATPase of porcine cortex.
1999 Feb 26
Sexual dimorphism in diethylstilbestrol-induced prolactin pituitary tumors in F344 rats.
2000 Aug
Differential estrogen receptor binding of estrogenic substances: a species comparison.
2000 Nov 15
Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.
2000 Sep
Relationship between expression of sex steroid receptors and structure of the seminal vesicles after neonatal treatment of rats with potent or weak estrogens.
2001 Dec
Increased exocytosis of secretory granules in contrast to reduced serum hormone levels in pituitary adenomas of humans and rats treated with dopamine agonist.
2001 Jun
Uterine adenocarcinoma in mice treated neonatally with genistein.
2001 Jun 1
Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods.
2001 May
Cell response endpoints enhance sensitivity of the immature mouse uterotropic assay.
2001 May-Jun
Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors.
2001 Nov 2
Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
2001 Sep 15
Improvement of a sensitive enzyme-linked immunosorbent assay for screening estrogen receptor binding activity.
2002 Dec
Increases in mouse uterine heat shock protein levels are a sensitive and specific response to uterotrophic agents.
2002 Dec
Induction of reproductive tract developmental abnormalities in the male rat by lowering androgen production or action in combination with a low dose of diethylstilbestrol: evidence for importance of the androgen-estrogen balance.
2002 Dec
Findings in female offspring of women exposed in utero to diethylstilbestrol.
2002 Feb
Estrogen mimics bind with similar affinity and specificity to the hepatic estrogen receptor in Atlantic salmon (Salmo salar) and rainbow trout (Oncorhynchus mykiss).
2002 Mar
Oxidative DNA damage induced by toluene is involved in its male reproductive toxicity.
2003 Jan
Endocrine disrupting chemicals: interference of thyroid hormone binding to transthyretins and to thyroid hormone receptors.
2003 Jan 31
In vitro modulation of prolactin mRNA by toxaphene and 3,3',4,4'-tetrachlorobiphenyl.
2003 Jul
Effects of endocrine disrupting compounds on the pathology and oestrogen receptor alpha and beta distribution in the uterus and cervix of ewe lambs.
2003 Nov
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
2003 Oct
Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen.
2003 Oct
Combined effects of tumor promoters and serum on proliferin mRNA induction: a biomarker sensitive to saccharin, 2,3,7,8-TCDD, and other compounds at minimal concentrations promoting C3H/10T1/2 cell transformation.
2003 Oct 24
Induction of vitellogenin synthesis in an Atlantic salmon (Salmo salar) hepatocyte culture: a sensitive in vitro bioassay for the oestrogenic and anti-oestrogenic activity of chemicals.
2003 Sep-Oct
Neonatal estrogenization leads to increased expression of cellular retinol binding protein 2 in the mouse reproductive tract.
2004 Apr
Diethylstilbestrol induces fish oocyte maturation.
2004 Mar 9
Patents

Patents

03989825
6
04055638
6
05030328
7
05811547
5
05962438
5
JP1040412A
9
JP2000044435A
34
JP2000159733A
5
JP2001048900A
5
JP2002511777A
414
JP2002525268A
31
JP2003529540A
49
JP2005145832A
5
JP2005519871A
28
JP2005523278A
25
JP2006502184A
41
JP2006507253A
19
JP2006519264A
58
JP2006528196A
42
JP2007508039A
114
JP2007520453A
33
JP2008533018A
15
JP2008533019A
34
JP2008539832A
82
JP2009519341A
24
JP2009525790A
101
JP2009537636A
13
JP2010525083A
52
JP2011528275A
455
JP2965160B2
10
JP4527401B2
32
JP4658037B2
37
JP4663232B2
15
JP4758474B2
87
JP4787165B2
101
JP4799864B2
33
JP4818917B2
31
JPH03134050A
5
JPH03220121A
5
JPH04358132A
5
JPH04358133A
5
JPH06345625A
5
JPH08283707A
5
JPH08283708A
5
JPH08337557A
5
JPH09275998A
5
JPH093014A
5
JPS59155337A
5
JPS60208905A
8
JPS6143101A
5
JPS6440412A
12

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous: Initial: 600-1,200 mg/day via slow injection for 5-10 days, then 300 mg/day for 10-20 days.
360-480 mg 3 times/day. Maintenance: 120-240 mg 3 times/day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: There was exposed three prostatic carcinoma cell lines (LNCaP, DU 145, and PC-3), three non-prostatic neoplastic cell lines (KB: epidermoid carcinoma, EJ: Bladder carcinoma, Daudi: Burkitt lymphoma), and one non-transformed embryonic fibroblast line (MRC-5) to diethylstilbestrol (DES), DES monophosphate, and DES diphosphate (DESDP), at levels comparable to those occurring in patients’ sera during DESDP infusions. At concentrations of 1–20 µg/ml the drugs showed marked, dose-dependent cytotoxicity towards all cell lines under study.
1–20 µg/ml
Name Type Language
FOSFESTROL SODIUM
MART.  
Common Name English
Fosfestrol tetrasodium [WHO-DD]
Common Name English
TETRASODIUM FOSFESTROL
Common Name English
FOSFESTROL TETRASODIUM SALT
MI  
Common Name English
FOSFESTROL SODIUM [MART.]
Common Name English
ANHYDROUS FOSFESTROL TETRASODIUM
Common Name English
FOSFESTROL TETRASODIUM SALT [MI]
Common Name English
FOSFESTROL TETRASODIUM
WHO-DD  
Common Name English
(E)-.ALPHA.,.ALPHA.'-DIETHYLSTILBENE-4,4'-DIOL BIS(DIHYDROGEN PHOSPHATE), TETRASODIUM SALT
Common Name English
Code System Code Type Description
RXCUI
281876
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m5550
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY Merck Index
CAS
23519-26-8
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
ALTERNATIVE
CAS
4719-75-9
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
CAS
22032-58-2
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
SUPERSEDED
EPA CompTox
DTXSID00963762
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
ECHA (EC/EINECS)
225-209-6
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
EVMPD
SUB02259MIG
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
SMS_ID
100000087018
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
PUBCHEM
3034148
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
FDA UNII
G9I1882VSD
Created by admin on Fri Dec 15 17:18:25 GMT 2023 , Edited by admin on Fri Dec 15 17:18:25 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FOSFESTROL
SUBSTANCE RECORD
Structure of FOSFESTROL SODIUM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966